New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS)

被引：11

作者：

Sharma, Shringi ^{[1
]}

Pepin, Xavier ^{[2
]}

Burri, Harini ^{[1
]}

Zheng, Lianqing ^{[1
]}

Kuptsova-Clarkson, Nataliya ^{[3
]}

de Jong, Anouk ^{[4
]}

Yu, Ting ^{[1
]}

MacArthur, Holly L. ^{[5
]}

Majewski, Michal ^{[5
]}

Ware, Joseph A. ^{[1
]}

Mann, James ^{[2
]}

Ramies, David ^{[1
]}

Munugalavadla, Veerendra ^{[1
]}

Sheridan, Louise ^{[2
]}

Tomkinson, Helen ^{[6
]}

机构：

[1] AstraZeneca, San Francisco, CA USA

[2] AstraZeneca, Macclesfield, Cheshire, England

[3] AstraZeneca, Gaithersburg, MD USA

[4] Acerta Pharma, Oss, Netherlands

[5] AstraZeneca, Mississauga, ON, Canada

[6] AstraZeneca, Cambridge, England

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146610

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4365

引用

页数：5

共 5 条

[1] Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors
Sharma, Shringi
Pepin, Xavier
Burri, Harini
Zheng, Lianqing
Kuptsova-Clarkson, Nataliya
de Jong, Anouk
Yu, Ting
MacArthur, Holly L.
Majewski, Michal
Byrd, John C.
Furman, Richard R.
Ware, Joseph A.
Mann, James
Ramies, David
Munugalavadla, Veerendra
Sheridan, Louise
Tomkinson, Helen
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (11): : 1294 - 1307
[2] Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study
Ikemura, Kenji
Oshima, Kosuke
Enokiya, Tomoyuki
Okamoto, Akiharu
Oda, Hiroyasu
Mizuno, Toshiro
Ishinaga, Hajime
Muraki, Yuichi
Iwamoto, Takuya
Takeuchi, Kazuhiko
Katayama, Naoyuki
Okuda, Masahiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 943 - 949
[3] Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study
Kenji Ikemura
Kosuke Oshima
Tomoyuki Enokiya
Akiharu Okamoto
Hiroyasu Oda
Toshiro Mizuno
Hajime Ishinaga
Yuichi Muraki
Takuya Iwamoto
Kazuhiko Takeuchi
Naoyuki Katayama
Masahiro Okuda
Cancer Chemotherapy and Pharmacology, 2017, 79 : 943 - 949
[4] Effect of Proton pump inhibitor co-administration on virological response in hepatitis C genotype 1 patients treated with Sofosbuvir plus Ledipsavir
Alsahhar, Jamil S.
Nazario, Hector E.
Gautam, Manjushree
Gonzalez, Stevan A.
Ramirez-Vega, Ruben
Ash-Faq, Mohammad
Ndungu, Milka
Teachenor, Olga
Gonzales, Gabriel R.
Modi, Apurva A.
HEPATOLOGY, 2015, 62 : 802A - 803A
[5] Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies
Cojutti, Pier Giorgio
Candoni, Anna
Lazzarotto, Davide
Rabassi, Nicholas
Fanin, Renato
Hope, William
Pea, Federico
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (11) : 2544 - 2550

← 1 →